This is the second-largest retrospective analysis addressing the controversy of whether adult
rhabdomyosarcoma (RMS) should be treated with chemotherapy regimens adopted from …

Simple Summary Due to their rarity, we still know comparatively little about
rhabdomyosarcomas (RMS) in adolescents and young adults (AYA). Factors responsible for …

Background Outcomes in adult patients with rhabdomyosarcoma are poor, with a 5-year
survival rate of approximately 30%. The current study aimed to compare the clinical …

Background: Adults with rhabdomyosarcoma (RMS) have a worse clinical outcome
compared to pediatric cases. In the present study, the failure pattern and clinical outcome of …

Rhabdomyosarcoma (RMS) is rare in adults and it is generally characterized by poor
outcome. In a previous retrospective study, we demonstrated a better prognosis in adults …

PURPOSE: Rhabdomyosarcoma (RMS) is a pediatric sarcoma rarely occurring in adults. For
unknown reasons, adults with RMS have worse outcomes than do children. METHODS AND …

Purpose: Rhabdomyosarcoma (RMS) has a worse prognosis in adults than in children, but
there is evidence of a better outcome in the former if treated using a pediatric-like approach …

Background Compared to pediatric patients, adult rhabdomyosarcoma (RMS) patients have
poor prognoses, but the differences in prognoses and treatment sensitivity between …

Simple Summary Rhabdomyosarcoma is the most frequent soft tissue sarcoma of childhood,
but can occur at any age. Adolescent and young adult patients with rhabdomyosarcoma …

Background Outcome of relapsed disease of localized rhabdomyosarcoma remains poor.
An individual treatment approach considering the initial systemic treatment and risk group …